Cue Biopharma Names Shao-Lee Lin CEO, Plans Phase 1 CUE-401 and Phase 2 Launch
Dr. Lin brings over 25 years of biopharma leadership including founding Acelyrin, raising over $1 billion and completing a $2 billion IPO, as she succeeds Lucinda Warren as CEO, President and Director. Cue plans to advance CUE-401 into Phase 1 and launch a Phase 2 allergic disease program in 2H2026.
1. Executive Leadership Change
Cue Biopharma appointed Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Board Director, succeeding interim CEO Lucinda Warren. The board expects Dr. Lin’s experience to guide Cue’s transition into a clinical-stage company and drive its growth strategy.
2. Proven Track Record and Fundraising
Dr. Lin brings over 25 years of leadership, having founded Acelyrin and raised more than $1 billion in capital while achieving a $2 billion IPO valuation. Her prior roles include head of R&D at Horizon Therapeutics and executive positions at AbbVie, Gilead and Amgen, contributing to multiple approved medicines.
3. Pipeline Developments and Near-Term Inflection
Cue plans to advance its lead autoimmune candidate, CUE-401, into Phase 1 trials and has initiated a Phase 2 program for its anti-IgE antibody targeting allergic disease. The company anticipates a potential near-term inflection point in the second half of 2026 with these pipeline milestones.